• 1. Achieving Efficient Uranium Extraction by In-situ Ultrasonic Texturization of Commercial Fe Powder
  BomingZhu,HongweiWu,JieKang,XiaofangYu,TaoChen,RuCheng,GuolinYang,WencaiBai,WenkunZhu,RongHe
• 2. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416
• 3. Aggregation-induced emission based on a fluorinated macrocycle: visualizing spontaneous and ultrafast solid-state molecular motions at room temperature via F?F interactions?
  Mei Zhang,Jingjing Guo,Tingting Liu,Zhanyu He,Majeed Irfan,Zujin Zhao,Zhuo Zeng J. Mater. Chem. C, 2020,8, 14919-14924
• 4. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 5. An automated in-chip-catalytic–spectrophotometric method for determination of copper(ii) using a multisyringe flow injection analysis-multipumping flow system?
  Camelia Henríquez,Edwin Palacio,Víctor Cerdà Anal. Methods, 2014,6, 8494-8504

Professional Introduction to 1H-Pyrazole, 1-(2-bromoethyl)-3,5-dimethyl- (CAS No: 67000-35-5)

The compound 1H-Pyrazole, 1-(2-bromoethyl)-3,5-dimethyl- (CAS No: 67000-35-5) is a significant intermediate in the field of pharmaceutical and agrochemical research. This heterocyclic compound belongs to the pyrazole family, which is renowned for its broad spectrum of biological activities. The structural features of this molecule, particularly the presence of a bromoethyl group and dimethyl substituents at the 3 and 5 positions of the pyrazole ring, make it a versatile scaffold for further chemical modifications and biological evaluations.

Pyrazoles are nitrogen-containing five-membered rings that have garnered considerable attention due to their role as pharmacophores in numerous therapeutic agents. The introduction of bromoethyl and dimethyl groups into the pyrazole core enhances its reactivity and potential for functionalization. This modification allows for further derivatization through nucleophilic substitution or cross-coupling reactions, making it a valuable building block in medicinal chemistry.

In recent years, the pharmaceutical industry has seen a surge in the development of novel compounds based on pyrazole derivatives. These derivatives exhibit a wide range of biological activities, including anti-inflammatory, antiviral, anticancer, and antimicrobial properties. The compound 1-(2-bromoethyl)-3,5-dimethylpyrazole is particularly interesting because it combines the advantageous properties of pyrazole with additional functional groups that can interact with biological targets.

One of the most compelling aspects of this compound is its potential as a precursor for drug discovery. The bromoethyl group serves as a handle for further chemical transformations, enabling the synthesis of more complex molecules. For instance, palladium-catalyzed cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings can be employed to introduce aryl or amino groups at various positions of the pyrazole ring. These reactions are highly efficient and allow for precise control over the molecular architecture.

The dimethyl groups at the 3 and 5 positions contribute to the stability of the pyrazole ring while also influencing its electronic properties. This can be exploited to fine-tune the interactions between the compound and biological targets. For example, electron-withdrawing groups can be introduced to enhance binding affinity to certain enzymes or receptors.

Recent studies have highlighted the importance of pyrazole derivatives in addressing various therapeutic challenges. A notable area of research has been their application in oncology. Several pyrazole-based compounds have shown promising activity against different cancer cell lines by inhibiting key signaling pathways involved in tumor growth and progression. The compound 1-(2-bromoethyl)-3,5-dimethylpyrazole could potentially serve as a lead structure for developing new anticancer agents.

In addition to oncology, this compound has also been explored for its potential in antimicrobial applications. The growing threat of antibiotic-resistant bacteria has necessitated the discovery of novel antimicrobial agents. Pyrazole derivatives have demonstrated efficacy against both Gram-positive and Gram-negative bacteria by targeting essential bacterial processes such as DNA replication or cell wall synthesis.

The agrochemical sector has also benefited from the versatility of pyrazole derivatives. These compounds have been incorporated into crop protection agents that offer improved efficacy against pests and diseases while maintaining environmental safety. The structural features of 1-(2-bromoethyl)-3,5-dimethylpyrazole make it a suitable candidate for developing new agrochemical formulations that address emerging challenges in agriculture.

The synthesis of this compound typically involves multi-step organic reactions starting from commercially available precursors. Key steps include bromination of an appropriate pyrazole derivative followed by alkylation with ethylene oxide or a related reagent to introduce the bromoethyl group. The dimethyl groups are usually introduced via methylation reactions using reagents such as methyl iodide or dimethyl sulfate.

Advances in synthetic methodologies have significantly improved the efficiency and scalability of producing pyrazole derivatives like 1H-Pyrazole, 1-(2-bromoethyl)-3,5-dimethyl- (CAS No: 67000-35-5). Techniques such as flow chemistry and microwave-assisted synthesis have enabled faster reaction times and higher yields under milder conditions. These innovations are crucial for reducing costs and improving sustainability in pharmaceutical manufacturing.

The biological evaluation of this compound is essential to determine its potential therapeutic applications. In vitro assays are commonly used to assess its activity against various biological targets such as enzymes or receptors. Additionally, in vivo studies can provide insights into its pharmacokinetic properties and toxicity profile.

Computational methods have also played a significant role in understanding the interactions between pyrazole derivatives and biological targets. Molecular docking simulations can predict binding affinities and identify key interaction sites between the compound and its target proteins or enzymes. These predictions can guide experimental efforts by prioritizing promising lead structures for further optimization.

The future prospects for 1H-Pyrazole, 1-(2-bromoethyl)-3,5-dimethyl- (CAS No: 67000-35-5) are promising given its structural versatility and potential applications across multiple domains. Continued research efforts are expected to yield novel derivatives with enhanced biological activity and improved pharmacological profiles.

In conclusion,1H-Pyrazole, 1-(2-bromoethyl)-3,5-dimethyl- (CAS No: 67000-35-5) represents an important intermediate in pharmaceutical and agrochemical research due to its unique structural features and functionalization potential. Its role as a building block for synthesizing biologically active compounds underscores its significance in drug discovery efforts aimed at addressing various therapeutic challenges.

• 101395-72-6(2-(5-methyl-1H-pyrazol-1-yl)ethan-1-amine)
• 647824-46-2(1-tert-Butyl-3,5-dimethyl-1H-pyrazole)
• 83612-48-0(Ethanone,2-bromo-1-(3,5-dimethyl-1H-pyrazol-1-yl)-)
• 62821-88-9(2-(3,5-dimethyl-1H-pyrazol-1-yl)ethan-1-amine)
• 20000-80-0(2-(3,5-dimethyl-1H-pyrazol-1-yl)ethan-1-ol)
• 62821-89-0(3-(3,5-Dimethyl-1h-pyrazol-1-yl)propan-1-amine)
• 17629-26-4(1-Ethyl-4-iodo-3,5-dimethyl-1H-pyrazole)
• 13369-74-9(1-Allyl-3,5-dimethylpyrazole)
• 1134684-85-7(2-(3,5-Dimethyl-1H-pyrazol-1-yl)acetonitrile)
• 724704-85-2(1-(2-Bromoethyl)-3-methyl-1H-pyrazole)